We are not currently shipping Sylvant.
Information about Sylvant (Siltuximab)
Sylvant (Siltuximab) is a monoclonal antibody used primarily in the treatment of certain cancers and immune system disorders. It works by targeting and binding to interleukin-6 (IL-6), a protein involved in inflammation and immune responses. By inhibiting IL-6, Siltuximab helps reduce inflammation and the growth of cancer cells, making it effective for conditions like multicentric Castleman disease and some cancers. Sylvant is administered intravenously and is usually prescribed under the supervision of an oncologist or specialist.
Product Highlights
- A rare and serious condition characterized by abnormal growth of lymph nodes and other tissues, which can lead to complications like organ damage and impaired immune function. Siltuximab is used in patients with MCD who do not have HIV or human herpesvirus-8 (HHV-8) infection.
- Sylvant may be used in the treatment of specific cancers, such as some types of non-Hodgkin lymphoma, although its use in cancer treatment is less common and subject to specific clinical guidelines.
Key Ingredient
Key Benefits
- Sylvant can help reduce symptoms and improve quality of life for patients with MCD, leading to fewer complications related to the disease.
- By targeting IL-6, Sylvant can help decrease the inflammation that occurs in autoimmune disorders and certain cancers.
- In some cancers, Sylvant may help in controlling tumor growth and reducing symptoms, particularly in conditions where IL-6 is contributing to the disease progression.
- In MCD, the reduction in IL-6 activity can lead to a decrease in the size of swollen lymph nodes, alleviating pain and discomfort.
Direction of Use
- Sylvant is given through an intravenous (IV) infusion in a clinical setting. The infusion is typically given every 3 weeks, depending on the condition being treated.
- Before administration, Sylvant must be reconstituted from a vial of powder, and this procedure is typically done by a trained healthcare professional.
- The standard dosage for MCD is 11 mg/kg of body weight, infused over 1 hour. Dosage for other indications may vary depending on the condition and the doctor's recommendations.
Safety Concerns
- The most frequent side effects include fever, fatigue, headache, nausea, and diarrhea, which are typically mild and short-lived.
- More serious side effects can include infections (such as upper respiratory tract infections, pneumonia, or sepsis), infusion reactions (e.g., fever, chills, rash), and an increased risk of certain types of cancers due to immune suppression.
- Siltuximab can increase the risk of blood clots in some individuals, requiring close monitoring during treatment.
- Liver enzyme levels may be affected during treatment, and liver function should be monitored regularly.
- Serious allergic reactions can occur, including anaphylaxis, and patients should be monitored during the infusion for any signs of such reactions.
Avoid Sylvant (Siltuximab) If
- Do not use Sylvant if you have a known hypersensitivity or allergic reaction to Siltuximab or any of its components.
- If you have a current serious infection, including tuberculosis or opportunistic infections, Sylvant should be avoided until the infection is resolved.
- If you have severe liver disease or significant liver dysfunction, use of Sylvant may not be advisable.
- Sylvant should not be used during pregnancy unless the potential benefits outweigh the risks. It is also not recommended while breastfeeding, as it may affect the baby.
- Patients who have had severe reactions to similar monoclonal antibodies should not receive Sylvant.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.